Progyny Q3 revenue beats expectations on robust member engagement, authorises $200 mln share buyback

Progyny

06/11/2025 21:36

Overview

Progyny Q3 2025 revenue grows 9.3%, beating analyst expectations

Adjusted EBITDA for Q3 2025 beats analyst estimates, reflecting strong operational performance

Company announces $200 mln share repurchase program, indicating confidence in financial position

Outlook

Progyny raises full-year 2025 revenue guidance to $1.263 bln-$1.278 bln

Company expects 4Q 2025 revenue between $292.7 mln and $307.7 mln

Result Drivers

MEMBER ENGAGEMENT - Strong member engagement exceeded expectations, driving revenue growth, per CEO Pete Anevski

NEW CLIENTS - Over 80 new clients and 900,000 new lives added, with near 100% retention, boosting growth

PROGRAM SUCCESS - New programs like pregnancy-postpartum and menopause resonate in the market, contributing to growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$313.35 mln
$299.26 mln (10 Analysts)
Q3 EPS
$0.15
Q3 Net Income
$13.86 mln
Q3 Adjusted EBITDA
Beat
$54.97 mln
$46.70 mln (10 Analysts)
Q3 Gross Profit
$72.84 mln
Q3 Pretax Profit
$23.96 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the managed healthcare peer group is "buy"

Wall Street's median 12-month price target for Progyny Inc is $30.00, about 37.1% above its November 5 closing price of $18.88

The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 30 three months ago

Press Release: ID:nGNX3gSsJx

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)